PDF(Pubmed)
Abstract：
BACKGROUND: Most premenopausal patients with early breast cancer (eBC) are diagnosed with hormone receptor-positive disease and therefore candidate for adjuvant endocrine therapy (ET).
METHODS: The Gruppo Italiano Mammella (GIM) 23-POSTER (GIM23) is a multicenter, prospective, observational study conducted in 26 Italian institutions, aiming to evaluate ET choices for premenopausal patients affected by hormone receptor-positive eBC in a real-world setting. Here we report also the results in terms of type of ET prescribed according to the definition of high-risk patients by monarchE and NATALEE trials.
RESULTS: Between October 2019 and June 2022, 600 premenopausal patients were included, with a median age of 46 years. Almost half (271, 45.2 %) of the patients had stage I disease, while 254 (42.3 %) and 60 (10.0 %) patients had stage II and III, respectively. Overall, 149 (25.1 %) patients received tamoxifen alone, 83 (14.0 %) tamoxifen with ovarian function suppression (OFS), while 361 (60.9 %) received aromatase inhibitor (AI) with OFS. Patients treated with AI and OFS had higher number of metastatic axillary nodes, higher grade and more often received chemotherapy (all p < 0.001). According to the inclusion criteria of the monarchE and NATALEE trials, 81 patients (15.6 %) were considered high-risk for the monarchE and received AI with OFS in 88.9 % of the cases, while 231 patients (44.4 %) were considered high-risk for the NATALEE trial and received AI with OFS in 74.5 % of cases.
CONCLUSIONS: AI with OFS is the most prescribed adjuvant ET among premenopausal patients, especially in the presence of high-risk features.
METHODS: The Gruppo Italiano Mammella (GIM) 23-POSTER (GIM23) is a multicenter, prospective, observational study conducted in 26 Italian institutions, aiming to evaluate ET choices for premenopausal patients affected by hormone receptor-positive eBC in a real-world setting. Here we report also the results in terms of type of ET prescribed according to the definition of high-risk patients by monarchE and NATALEE trials.
RESULTS: Between October 2019 and June 2022, 600 premenopausal patients were included, with a median age of 46 years. Almost half (271, 45.2 %) of the patients had stage I disease, while 254 (42.3 %) and 60 (10.0 %) patients had stage II and III, respectively. Overall, 149 (25.1 %) patients received tamoxifen alone, 83 (14.0 %) tamoxifen with ovarian function suppression (OFS), while 361 (60.9 %) received aromatase inhibitor (AI) with OFS. Patients treated with AI and OFS had higher number of metastatic axillary nodes, higher grade and more often received chemotherapy (all p < 0.001). According to the inclusion criteria of the monarchE and NATALEE trials, 81 patients (15.6 %) were considered high-risk for the monarchE and received AI with OFS in 88.9 % of the cases, while 231 patients (44.4 %) were considered high-risk for the NATALEE trial and received AI with OFS in 74.5 % of cases.
CONCLUSIONS: AI with OFS is the most prescribed adjuvant ET among premenopausal patients, especially in the presence of high-risk features.
摘要：
背景：大多数绝经前早期乳腺癌（eBC）患者被诊断为激素受体阳性疾病，因此是辅助内分泌治疗（ET）的候选人。
方法：GruppoItalianoMammella（GIM）23-POSTER（GIM23）是一个多中心，prospective,在26个意大利机构进行的观察性研究，旨在评估在现实世界中接受激素受体阳性eBC影响的绝经前患者的ET选择。在这里，我们还报告了根据君主和NATALEE试验对高危患者的定义所规定的ET类型的结果。
结果：在2019年10月至2022年6月之间，纳入了600名绝经前患者，平均年龄为46岁。几乎一半（271，45.2％）的患者患有I期疾病，而254例（42.3%）和60例（10.0%）患者有II期和III期，分别。总的来说,149例（25.1%）患者单独接受他莫昔芬，83（14.0%）他莫昔芬伴卵巢功能抑制（OFS），而361（60.9%）接受芳香化酶抑制剂（AI）与OFS。接受AI和OFS治疗的患者有更多的转移性腋窝淋巴结，更高的级别和更经常接受化疗(所有p<0.001)。根据君主和娜塔莉审判的纳入标准，81名患者（15.6%）被认为是君主的高风险，88.9%的患者接受了OFS的AI治疗，而231例患者(44.4%)被认为是NATALEE试验的高危患者,74.5%的患者接受AI和OFS.
结论：AI伴OFS是绝经前患者中规定最多的辅助ET，特别是在存在高风险特征的情况下。
方法：GruppoItalianoMammella（GIM）23-POSTER（GIM23）是一个多中心，prospective,在26个意大利机构进行的观察性研究，旨在评估在现实世界中接受激素受体阳性eBC影响的绝经前患者的ET选择。在这里，我们还报告了根据君主和NATALEE试验对高危患者的定义所规定的ET类型的结果。
结果：在2019年10月至2022年6月之间，纳入了600名绝经前患者，平均年龄为46岁。几乎一半（271，45.2％）的患者患有I期疾病，而254例（42.3%）和60例（10.0%）患者有II期和III期，分别。总的来说,149例（25.1%）患者单独接受他莫昔芬，83（14.0%）他莫昔芬伴卵巢功能抑制（OFS），而361（60.9%）接受芳香化酶抑制剂（AI）与OFS。接受AI和OFS治疗的患者有更多的转移性腋窝淋巴结，更高的级别和更经常接受化疗(所有p<0.001)。根据君主和娜塔莉审判的纳入标准，81名患者（15.6%）被认为是君主的高风险，88.9%的患者接受了OFS的AI治疗，而231例患者(44.4%)被认为是NATALEE试验的高危患者,74.5%的患者接受AI和OFS.
结论：AI伴OFS是绝经前患者中规定最多的辅助ET，特别是在存在高风险特征的情况下。
